Conclusion: Low‐dose BCMA/CD19 dual CAR‐T cells are safe and can deplete B cells and plasma cells in patients with refractory MG without lymphodepletion, resulting in rapid clinical improvement. This evidence concerns the gene CD19 and myasthenia gravis.